Literature DB >> 18343944

Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.

Masaji Tani1, Manabu Kawai, Motoki Miyazawa, Seiko Hirono, Shinomi Ina, Ryohei Nishioka, Yoichi Fujita, Kazuhisa Uchiyama, Hiroki Yamaue.   

Abstract

BACKGROUND: Prognosis of the patients with pancreatic adenocarcinoma is still poor due to a recurrence, and liver metastasis is a distant metastasis that is foreboded the short survival period.
METHODS: Between 1999 and 2005, 68 patients for pancreatic adenocarcinoma underwent a pancreaticoduodenectomy (n = 17), a pylorus-preserving pancreaticoduodenectomy (n = 27), distal pancreatectomy (n = 22), or total pancreatectomy (n = 2) with an extensive lymph node dissection.
RESULTS: A tumor recurrence occurred to 55 patients (13 of the liver, 21 of the local recurrence, 16 of peritoneal dissemination, three of the lymph node, and two of lung). The low tumor grade and female demonstrated a risk factor for a liver metastasis (P = 0.043, P = 0.031). A logistic regression analysis demonstrated female (P = 0.02) and low tumor grade (P = 0.04) as independent risk factors for recurrence with liver metastasis. The median survival time (MST) was 13.6 months, and MST of patients with a liver metastasis as an initial recurrent site was 13.7 months; the liver metastasis as an initial recurrent site has no impact on the MST after pancreatic resection.
CONCLUSIONS: We concluded potentially supporting the hypothesis that even patients thought to be at higher risk of liver metastasis may still be given the chance of resection, considering the satisfying survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343944     DOI: 10.1007/s00423-008-0296-4

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  31 in total

Review 1.  Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma.

Authors:  Ilka Vogel; Holger Kalthoff; Doris Henne-Bruns; Bernd Kremer
Journal:  Pancreatology       Date:  2002       Impact factor: 3.996

2.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

3.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

4.  Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings.

Authors:  Shoichi Hishinuma; Yoshiro Ogata; Moriaki Tomikawa; Iwao Ozawa; Kaoru Hirabayashi; Seiji Igarashi
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

5.  Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection.

Authors:  Hiroki Yamaue; Masaji Tani; Hironobu Onishi; Hiroyuki Kinoshita; Mikihito Nakamori; Shozo Yokoyama; Makoto Iwahashi; Kazuhisa Uchiyama
Journal:  Pancreas       Date:  2002-11       Impact factor: 3.327

6.  A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer.

Authors:  Masayuki Imamura; Ryuichiro Doi; Toshihide Imaizumi; Akihiro Funakoshi; Hideyuki Wakasugi; Makoto Sunamura; Yoshiro Ogata; Shoichi Hishinuma; Takehide Asano; Takashi Aikou; Ryo Hosotani; Shunzo Maetani
Journal:  Surgery       Date:  2004-11       Impact factor: 3.982

7.  Pancreatic Cancer Registry in Japan: 20 years of experience.

Authors:  Seiki Matsuno; Shinichi Egawa; Shoji Fukuyama; Fuyuhiko Motoi; Makoto Sunamura; Shuji Isaji; Toshihide Imaizumi; Shuichi Okada; Hiroyuki Kato; Kouichi Suda; Akimasa Nakao; Takehisa Hiraoka; Ryo Hosotani; Kazunori Takeda
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

8.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

9.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.

Authors:  M Wagner; C Redaelli; M Lietz; C A Seiler; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2004-05       Impact factor: 6.939

10.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

View more
  6 in total

1.  Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Retrospective Study.

Authors:  Koki Hayashi; Yoshihiro Ono; Manabu Takamatsu; Atsushi Oba; Hiromichi Ito; Takafumi Sato; Yosuke Inoue; Akio Saiura; Yu Takahashi
Journal:  Ann Surg Oncol       Date:  2022-03-01       Impact factor: 5.344

2.  Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection.

Authors:  Kaitlyn J Kelly; Joyce Wong; Rebecca Gladdy; Kimberly Moore-Dalal; Yanghee Woo; Mithat Gonen; Murray Brennan; Peter Allen; Yuman Fong; Daniel Coit
Journal:  Ann Surg Oncol       Date:  2009-09-18       Impact factor: 5.344

3.  Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Ding Ding; Ammar A Javed; Richard A Burkhart; Jun Yu; Inne H Borel Rinkes; I Quintus Molenaar; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg Oncol       Date:  2018-06-14       Impact factor: 5.344

4.  Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?

Authors:  Emmanuel Buc; David Orry; Olivier Antomarchi; Johan Gagnière; David Da Ines; Denis Pezet
Journal:  World J Surg Oncol       Date:  2014-11-18       Impact factor: 2.754

5.  A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection.

Authors:  Chaobin He; Xin Huang; Yu Zhang; Zhiyuan Cai; Xiaojun Lin; Shengping Li
Journal:  Front Oncol       Date:  2019-11-12       Impact factor: 6.244

6.  Rectal metastasis from a previously resected carcinoma of the pancreas: a case report.

Authors:  Jing Sun; Xiao Zhang; He Huang; Yi Zhang; Kai Wang; Shiyun Cui
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.